Can Full-Body scans spot cancer early in High-Risk families?

NCT ID NCT02950987

Ongoing Diagnosis Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether whole body MRI scans can help find cancers early in children and adults with Li-Fraumeni syndrome, a genetic condition that greatly raises cancer risk. About 150 participants will receive annual whole body MRI scans for four years to see if they keep coming back for screening and how many cancers are detected. The goal is to see if this imaging approach is a practical and effective screening tool for this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Whole Body MRI (imaging device)
What this could lead to: If successful, this could establish whole body MRI as a standard screening method to catch cancers early in people with Li-Fraumeni syndrome, potentially improving survival.
What could go wrong: This is an observational screening study, not a treatment trial. It may not prove that earlier detection actually improves outcomes, and false positives could cause unnecessary anxiety or procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL CENTRAL HYPOVENTILATION SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central hypoventilation syndrome, congenital, 1, with or without Hirschsprung disease hereditary pheochromocytoma-paraganglioma hereditary retinoblastoma Li-Fraumeni syndrome multiple endocrine neoplasia type 1 multiple endocrine neoplasia type 2 neuroblastoma opsoclonus-myoclonus syndrome rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome von Hippel-Lindau disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LI-FRAUMENI SYNDROME

Contacts and locations

Locations

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.